Compare Stocks → The only accurate crypto trading system I know … (From Weiss Ratings) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison CVE:NVHTSE:ONC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNVHNovoheartC$0.53+1.9%C$0.53C$0.26▼C$0.72C$99.98MN/A33,593 shs23,066 shsONCOncolytics BiotechC$1.44+0.7%C$1.44C$1.20▼C$4.49C$108.61M1.4977,414 shs26,205 shs7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNVHNovoheart0.00%0.00%0.00%0.00%0.00%ONCOncolytics Biotech-2.05%-2.72%+3.62%-13.86%-8.92%top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNVHNovoheartN/AN/AN/AN/AN/AN/AN/AN/AONCOncolytics Biotech0.6035 of 5 stars3.50.00.00.01.10.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNVHNovoheartN/AN/AN/AN/AONCOncolytics Biotech3.00BuyC$6.00316.67% UpsideCurrent Analyst RatingsLatest NVH, FARN, OBD, and ONC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/4/2024ONCOncolytics BiotechRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperformC$3.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNVHNovoheartC$423.50K236.08C$0.07 per share7.46C$0.12 per share4.34ONCOncolytics BiotechN/AN/AC$0.34 per share4.22C$0.37 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNVHNovoheartN/A-C$0.04N/A∞N/AN/AN/AN/AN/AONCOncolytics Biotech-C$27.75M-C$0.41N/A∞N/AN/A-102.66%-55.47%5/3/2024 (Estimated)Latest NVH, FARN, OBD, and ONC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/7/2024Q4 2023ONCOncolytics Biotech-C$0.15-C$0.05+C$0.10-C$0.05N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNVHNovoheartN/AN/AN/AN/AN/AONCOncolytics BiotechN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNVHNovoheart27.626.136.05ONCOncolytics Biotech1.549.018.86OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNVHNovoheartN/AONCOncolytics Biotech6.98%Insider OwnershipCompanyInsider OwnershipNVHNovoheartN/AONCOncolytics Biotech6.24%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableNVHNovoheartN/A188.64 millionN/ANot OptionableONCOncolytics Biotech2975.42 millionN/ANot OptionableNVH, FARN, OBD, and ONC HeadlinesSourceHeadlineKrystal Biotech gets grant for pharmaceutical composition for cancer treatment using recombinant HSV-1 viruspharmaceutical-technology.com - April 23 at 9:08 AMOutrun Therapeutics announces launch with $10m seed fundingpharmaceutical-technology.com - April 18 at 7:38 AMBiotech expansion for Japanese firm in Holly Springs driven by talent pool, universitiescarolinapublicpress.org - April 17 at 10:38 AMStocks in play: Oncolytics Biotech® Inc.ca.finance.yahoo.com - April 11 at 3:56 PMOncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDAfinance.yahoo.com - April 11 at 8:38 AMTransgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024markets.businessinsider.com - April 10 at 6:01 PMOncolytics Biotech is undervalued, Raymond James sayscantechletter.com - April 5 at 3:37 PMOncolytics Biotech (TSE:ONC) Trading Up 10.7%marketbeat.com - April 4 at 10:46 AMClosing Bell: Oncolytics Bio down on Friday (ONC)theglobeandmail.com - March 16 at 10:14 AMFutures Retreat Sharplymsn.com - March 11 at 4:05 PMOncolytics Biotech Inc.: Oncolytics Biotech Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCANfinanznachrichten.de - March 6 at 4:39 PMEcon Corp Services DBA Investorideas.com: Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winningfinanznachrichten.de - March 6 at 4:39 PMA Preview Of Oncolytics Biotech's Earningsbenzinga.com - March 6 at 4:39 PMOncolytics Biotech Inc ONCmorningstar.com - March 2 at 6:22 PMReiterating Buy Rating: Expanding Potential of Pelareorep in Oncolytics Biotech’s Pipelinemarkets.businessinsider.com - February 15 at 9:24 AMCancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatmentsfinance.yahoo.com - February 15 at 9:24 AMAnal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapiestheglobeandmail.com - February 14 at 2:36 PMUSA News Group: Pancreatic Cancer Treatments Poised for Major Advances in 2024finanznachrichten.de - February 7 at 11:03 AMKaliVir Announces Opening of GMP Cleanroom Facility, Increasing Manufacturing Capacity for Oncolytic Virusesfinance.yahoo.com - January 31 at 8:47 PMOncolytics Biotech Stock (NASDAQ:ONCY), Analyst Ratings, Price Targets, Predictionsbenzinga.com - January 6 at 3:30 PMJonesTrading Keeps Their Hold Rating on TRACON Pharmaceuticals (TCON)markets.businessinsider.com - December 14 at 8:26 AMOncolytics Biotech Inc.: Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCSfinanznachrichten.de - December 7 at 8:30 AMOncolytics Provides Update on Pancreatic Cancer Program for Pelareorepfinance.yahoo.com - November 9 at 7:48 AMOncolytics Biotech's Earnings Outlookbenzinga.com - November 3 at 6:37 PMNew MarketBeat Followers Over TimeCompany DescriptionsNovoheartCVE:NVHNovoheart Holdings Inc. operates as a stem cell biotechnology company in the United States. The company offers an array of next-generation human heart tissue prototypes. It provides MyHeart platform products, including human pluripotent stem cell-derived cardiomyocytes, human ventricular cardiac anisotropic sheet assays, and human ventricular cardiac tissue strips assays. The company also offers screening and phenotyping services; and consultation services, including mapping and designing preclinical studies that involve human embryonic or induced pluripotent stem cell-derived cardiomyocytes, prototyping custom bioreactor designs, and developing custom software for streamlining of screening platforms and analysis of acquired data. Novoheart Holdings Inc. has a collaboration with AstraZeneca to develop human-specific in vitro functional model of heart failure with preserved ejection fraction. The company is based in Vancouver, Canada.Oncolytics BiotechTSE:ONCOncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.